Targeting complexes of super‑enhancers is a promising strategy for cancer therapy (Review)
- Authors:
- Chuqian Zheng
- Min Liu
- Hong Fan
-
Affiliations: Department of Medical Genetics and Developmental Biology, School of Medicine, The Key Laboratory of Developmental Genes and Human Diseases, Ministry of Education, Southeast University, Nanjing, Jiangsu 210009, P.R. China - Published online on: July 10, 2020 https://doi.org/10.3892/ol.2020.11855
- Pages: 2557-2566
-
Copyright: © Zheng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
Banerji J, Rusconi S and Schaffner W: Expression of a beta-globin gene is enhanced by remote SV40 DNA sequences. Cell. 27:299–308. 1981. View Article : Google Scholar : PubMed/NCBI | |
Sur I and Taipale J: The role of enhancers in cancer. Nat Rev Cancer. 16:483–493. 2016. View Article : Google Scholar : PubMed/NCBI | |
Rickels R and Shilatifard A: Enhancer Logic and mechanics in development and disease. Trends Cell Biol. 28:608–630. 2018. View Article : Google Scholar : PubMed/NCBI | |
Bulger M and Groudine M: Functional and mechanistic diversity of distal transcription enhancers. Cell. 144:327–339. 2011. View Article : Google Scholar : PubMed/NCBI | |
Whyte WA, Orlando DA, Hnisz D, Abraham BJ, Lin CY, Kagey MH, Rahl PB, Lee TI and Young RA: Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell. 153:307–319. 2013. View Article : Google Scholar : PubMed/NCBI | |
Pott S and Lieb JD: What are super-enhancers? Nat Genet. 47:8–12. 2015. View Article : Google Scholar : PubMed/NCBI | |
Hnisz D, Abraham BJ, Lee TI, Lau A, Saint-Andre V, Sigova AA, Hoke HA and Young RA: Super-enhancers in the control of cell identity and disease. Cell. 155:934–947. 2013. View Article : Google Scholar : PubMed/NCBI | |
Christensen CL, Kwiatkowski N, Abraham BJ, Carretero J, Al-Shahrour F, Zhang T, Chipumuro E, Herter-Sprie GS, Akbay EA, Altabef A, et al: Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. Cancer Cell. 26:909–922. 2014. View Article : Google Scholar : PubMed/NCBI | |
Tsang FH, Law CT, Tang TC, Cheng CL, Chin DW, Tam WV, Wei L, Wong CC, Ng IO and Wong CM: Aberrant super-enhancer landscape in human hepatocellular carcinoma. Hepatology. 69:2502–2517. 2019.PubMed/NCBI | |
Xie JJ, Jiang YY, Jiang Y, Li CQ, Lim MC, An O, Mayakonda A, Ding LW, Long L, Sun C, et al: Super-Enhancer-driven long non-coding RNA LINC01503, regulated by tp63, is over-expressed and oncogenic in squamous cell carcinoma. Gastroenterology. 154:2137–2151. 2018. View Article : Google Scholar : PubMed/NCBI | |
Peng L, Jiang B, Yuan X, Qiu Y, Peng J, Huang Y, Zhang C, Zhang Y, Lin Z, Li J, et al: Super-Enhancer-associated long noncoding RNA HCCL5 is activated by zeb1 and promotes the malignancy of hepatocellular carcinoma. Cancer Res. 79:572–584. 2019. View Article : Google Scholar : PubMed/NCBI | |
Lin L, Huang M, Shi X, Mayakonda A, Hu K, Jiang YY, Guo X, Chen L, Pang B, Doan N, et al: Super-enhancer-associated MEIS1 promotes transcriptional dysregulation in Ewing sarcoma in co-operation with EWS-FLI1. Nucleic Acids Res. 47:1255–1267. 2019. View Article : Google Scholar : PubMed/NCBI | |
Cao X, Dang L, Zheng X, Lu Y, Lu Y, Ji R, Zhang T, Ruan X, Zhi J, Hou X, et al: Targeting super-enhancer-driven oncogenic transcription by cdk7 inhibition in anaplastic thyroid carcinoma. Thyroid. 29:809–823. 2019. View Article : Google Scholar : PubMed/NCBI | |
Wang L and Hu G: Remodeling super-enhancers and oncogenic transcription. Cell Cycle. 15:3157–3158. 2016. View Article : Google Scholar : PubMed/NCBI | |
Ma M, Ru Y, Chuang LS, Hsu NY, Shi LS, Hakenberg J, Cheng WY, Uzilov A, Ding W, Glicksberg BS, et al: Disease-associated variants in different categories of disease located in distinct regulatory elements. BMC Genomics. 16 (Suppl 8):S32015. View Article : Google Scholar | |
Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC and Croce CM: Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci USA. 79:7824–7827. 1982. View Article : Google Scholar : PubMed/NCBI | |
Taub R, Kirsch I, Morton C, Lenoir G, Swan D, Tronick S, Aaronson S and Leder P: Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci USA. 79:7837–7841. 1982. View Article : Google Scholar : PubMed/NCBI | |
Ar-Rushdi A, Nishikura K, Erikson J, Watt R, Rovera G and Croce CM: Differential expression of the translocated and the untranslocated c-myc oncogene in Burkitt lymphoma. Science. 222:390–393. 1983. View Article : Google Scholar : PubMed/NCBI | |
Erikson J, Ar-Rushdi A, Drwinga HL, Nowell PC and Croce CM: Transcriptional activation of the translocated c-myc oncogene in burkitt lymphoma. Proc Natl Acad Sci USA. 80:820–824. 1983. View Article : Google Scholar : PubMed/NCBI | |
Kubota S, Tokunaga K, Umezu T, Yokomizo-Nakano T, Sun Y, Oshima M, Tan KT, Yang H, Kanai A, Iwanaga E, et al: Lineage-specific RUNX2 super-enhancer activates MYC and promotes the development of blastic plasmacytoid dendritic cell neoplasm. Nat Commun. 10:16532019. View Article : Google Scholar : PubMed/NCBI | |
Chipumuro E, Marco E, Christensen CL, Kwiatkowski N, Zhang T, Hatheway CM, Abraham BJ, Sharma B, Yeung C, Altabef A, et al: CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. Cell. 159:1126–1139. 2014. View Article : Google Scholar : PubMed/NCBI | |
Sengupta S and George RE: Super-Enhancer-driven transcriptional dependencies in cancer. Trends Cancer. 3:269–281. 2017. View Article : Google Scholar : PubMed/NCBI | |
Hnisz D, Shrinivas K, Young RA, Chakraborty AK and Sharp PA: A Phase separation model for transcriptional control. Cell. 169:13–23. 2017. View Article : Google Scholar : PubMed/NCBI | |
Yoo H, Triandafillou C and Drummond DA: Cellular sensing by phase separation: Using the process, not just the products. J Biol Chem. 294:7151–7159. 2019. View Article : Google Scholar : PubMed/NCBI | |
Sabari BR, Dall'Agnese A, Boija A, Klein IA, Coffey EL, Shrinivas K, Abraham BJ, Hannett NM, Zamudio AV, Manteiga JC, et al: Coactivator condensation at super-enhancers links phase separation and gene control. Science. 361:eaar39582018. View Article : Google Scholar : PubMed/NCBI | |
Wang JT, Smith J, Chen BC, Schmidt H, Rasoloson D, Paix A, Lambrus BG, Calidas D, Betzig E and Seydoux G: Regulation of RNA granule dynamics by phosphorylation of serine-rich, intrinsically disordered proteins in C. elegans. Elife. 3:e45912014. View Article : Google Scholar | |
Wippich F, Bodenmiller B, Trajkovska MG, Wanka S, Aebersold R and Pelkmans L: Dual specificity kinase DYRK3 couples stress granule condensation/dissolution to mTORC1 signaling. Cell. 152:791–805. 2013. View Article : Google Scholar : PubMed/NCBI | |
Milin AN and Deniz AA: Reentrant phase transitions and non-equilibrium dynamics in membraneless organelles. Biochemistry. 57:2470–2477. 2018. View Article : Google Scholar : PubMed/NCBI | |
Nakamura Y, Hattori N, Iida N, Yamashita S, Mori A, Kimura K, Yoshino T and Ushijima T: Targeting of super-enhancers and mutant BRAF can suppress growth of BRAF-mutant colon cancer cells via repression of MAPK signaling pathway. Cancer Lett. 402:100–109. 2017. View Article : Google Scholar : PubMed/NCBI | |
Gunnell A, Webb HM, Wood CD, McClellan MJ, Wichaidit B, Kempkes B, Jenner RG, Osborne C, Farrell PJ and West MJ: RUNX super-enhancer control through the Notch pathway by Epstein-Barr virus transcription factors regulates B cell growth. Nucleic Acids Res. 44:4636–4650. 2016. View Article : Google Scholar : PubMed/NCBI | |
Ke L, Zhou H, Wang C, Xiong G, Xiang Y, Ling Y, Khabir A, Tsao GS, Zeng Y, Zeng M, et al: Nasopharyngeal carcinoma super-enhancer-driven ETV6 correlates with prognosis. Proc Natl Acad Sci USA. 114:9683–9688. 2017. View Article : Google Scholar : PubMed/NCBI | |
Dave K, Sur I, Yan J, Zhang J, Kaasinen E, Zhong F, Blaas L, Li X, Kharazi S, Gustafsson C, et al: Mice deficient of Myc super-enhancer region reveal differential control mechanism between normal and pathological growth. Elife. 6:e233822017. View Article : Google Scholar : PubMed/NCBI | |
Lai B, Lee JE, Jang Y, Wang L, Peng W and Ge K: MLL3/MLL4 are required for CBP/p300 binding on enhancers and super-enhancer formation in brown adipogenesis. Nucleic Acids Res. 45:6388–6403. 2017. View Article : Google Scholar : PubMed/NCBI | |
Chen K, Chen Z, Wu D, Zhang L, Lin X, Su J, Rodriguez B, Xi Y, Xia Z, Chen X, et al: Broad H3K4me3 is associated with increased transcription elongation and enhancer activity at tumor-suppressor genes. Nat Genet. 47:1149–1157. 2015. View Article : Google Scholar : PubMed/NCBI | |
Suzuki HI, Young RA and Sharp PA: Super-enhancer-mediated RNA processing revealed by integrative microrna network analysis. Cell. 168:1000–1014.e15. 2017. View Article : Google Scholar : PubMed/NCBI | |
Liang J, Zhou H, Gerdt C, Tan M, Colson T, Kaye KM, Kieff E and Zhao B: Epstein-Barr virus super-enhancer eRNAs are essential for MYC oncogene expression and lymphoblast proliferation. Proc Natl Acad Sci USA. 113:14121–14126. 2016. View Article : Google Scholar : PubMed/NCBI | |
Ounzain S and Pedrazzini T: Super-enhancer lncs to cardiovascular development and disease. Biochim Biophys Acta. 1863:1953–1960. 2016. View Article : Google Scholar : PubMed/NCBI | |
Peng L, Jiang B, Yuan X, Qiu Y, Peng J, Huang Y, Zhang C, Zhang Y, Lin Z, Li J, et al: Super-Enhancer-associated long noncoding RNA HCCL5 Is activated by zeb1 and promotes the malignancy of hepatocellular carcinoma. Cancer Res. 79:572–584. 2019. View Article : Google Scholar : PubMed/NCBI | |
Fontanals-Cirera B, Hasson D, Vardabasso C, Di Micco R, Agrawal P, Chowdhury A, Gantz M, de Pablos-Aragoneses A, Morgenstern A, Wu P, et al: Harnessing BET inhibitor sensitivity reveals AMIGO2 as a melanoma survival gene. Mol Cell. 68:731–744.e9. 2017. View Article : Google Scholar : PubMed/NCBI | |
Pelish HE, Liau BB, Nitulescu II, Tangpeerachaikul A, Poss ZC, Da SD, Caruso BT, Arefolov A, Fadeyi O, Christie AL, et al: Mediator kinase inhibition further activates super-enhancer- associated genes in AML. Nature. 526:273–276. 2015. View Article : Google Scholar : PubMed/NCBI | |
See YX, Wang BZ and Fullwood MJ: Chromatin interactions and regulatory elements in cancer: From bench to bedside. Trends Genet. 35:145–158. 2019. View Article : Google Scholar : PubMed/NCBI | |
Zhu X, Enomoto K, Zhao L, Zhu YJ, Willingham MC, Meltzer P, Qi J and Cheng SY: Bromodomain and extraterminal protein inhibitor JQ1 suppresses thyroid tumor growth in a mouse model. Clin Cancer Res. 23:430–440. 2017. View Article : Google Scholar : PubMed/NCBI | |
Augert A and MacPherson D: Treating transcriptional addiction in small cell lung cancer. Cancer Cell. 26:783–784. 2014. View Article : Google Scholar : PubMed/NCBI | |
Gerlach D, Tontsch-Grunt U, Baum A, Popow J, Scharn D, Hofmann MH, Engelhardt H, Kaya O, Beck J, Schweifer N, et al: The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML. Oncogene. 37:2687–2701. 2018. View Article : Google Scholar : PubMed/NCBI | |
Chen D, Zhao Z, Huang Z, Chen DC, Zhu XX, Wang YZ, Yan YW, Tang S, Madhavan S, Ni W, et al: Super enhancer inhibitors suppress MYC driven transcriptional amplification and tumor progression in osteosarcoma. Bone Res. 6:112018. View Article : Google Scholar : PubMed/NCBI | |
Kitazono M, Chuman Y, Aikou T and Fojo T: Construction of gene therapy vectors targeting thyroid cells: Enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the cyclic adenosine 3′,5′-monophosphate pathway and demonstration of activity in follicular and anaplastic thyroid carcinoma cells. J Clin Endocrinol Metab. 86:834–840. 2001. View Article : Google Scholar : PubMed/NCBI | |
Wong R, Ngoc P, Leong WZ, Yam A, Zhang T, Asamitsu K, Iida S, Okamoto T, Ueda R, Gray NS, et al: Enhancer profiling identifies critical cancer genes and characterizes cell identity in adult T-cell leukemia. Blood. 130:2326–2338. 2017. View Article : Google Scholar : PubMed/NCBI | |
Eliades P, Abraham BJ, Ji Z, Miller DM, Christensen CL, Kwiatkowski N, Kumar R, Njauw CN, Taylor M, Miao B, et al: High MITF expression is associated with super-enhancers and suppressed by CDK7 inhibition in melanoma. J Invest Dermatol. 138:1582–1590. 2018. View Article : Google Scholar : PubMed/NCBI | |
Kwiatkowski N, Zhang T, Rahl PB, Abraham BJ, Reddy J, Ficarro SB, Dastur A, Amzallag A, Ramaswamy S, Tesar B, et al: Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature. 511:616–620. 2014. View Article : Google Scholar : PubMed/NCBI | |
Sharifnia T, Wawer MJ, Chen T, Huang QY, Weir BA, Sizemore A, Lawlor MA, Goodale A, Cowley GS, Vazquez F, et al: Small-molecule targeting of brachyury transcription factor addiction in chordoma. Nat Med. 25:292–300. 2019. View Article : Google Scholar : PubMed/NCBI | |
Hu S, Marineau JJ, Rajagopal N, Hamman KB, Choi YJ, Schmidt DR, Ke N, Johannessen L, Bradley MJ, Orlando DA, et al: Discovery and characterization of SY-1365, a selective, covalent inhibitor of CDK7. Cancer Res. 79:3479–3491. 2019. View Article : Google Scholar : PubMed/NCBI | |
Dooley KE, Warburton A and McBride AA: Tandemly Integrated HPV16 Can Form a Brd4-dependent super-enhancer-like element that drives transcription of viral oncogenes. Mbio. 7:e01446–e01416. 2016. View Article : Google Scholar : PubMed/NCBI | |
Sengupta D, Kannan A, Kern M, Moreno MA, Vural E, Stack BJ, Suen JY, Tackett AJ and Gao L: Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma. Epigenetics. 10:460–466. 2015. View Article : Google Scholar : PubMed/NCBI | |
Loven J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, Bradner JE, Lee TI and Young RA: Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell. 153:320–334. 2013. View Article : Google Scholar : PubMed/NCBI | |
Zuber V, Bettella F, Witoelar A, Andreassen OA, Mills IG and Urbanucci A: Bromodomain protein 4 discriminates tissue-specific super-enhancers containing disease-specific susceptibility loci in prostate and breast cancer. BMC Genomics. 18:2702017. View Article : Google Scholar : PubMed/NCBI | |
Chapuy B, McKeown MR, Lin CY, Monti S, Roemer MG, Qi J, Rahl PB, Sun HH, Yeda KT, Doench JG, et al: Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell. 24:777–790. 2013. View Article : Google Scholar : PubMed/NCBI | |
Xiong L, Wu F, Wu Q, Xu L, Cheung OK, Kang W, Mok MT, Szeto L, Lun CY, Lung RW, et al: Aberrant enhancer hypomethylation contributes to hepatic carcinogenesis through global transcriptional reprogramming. Nat Commun. 10:3352019. View Article : Google Scholar : PubMed/NCBI | |
Andricovich J, Perkail S, Kai Y, Casasanta N, Peng W and Tzatsos A: Loss of KDM6A activates super-enhancers to induce gender-specific squamous-like pancreatic cancer and confers sensitivity to bet inhibitors. Cancer Cell. 33:512–526.e8e0. 2018. View Article : Google Scholar : PubMed/NCBI | |
Gelato KA, Schöckel L, Klingbeil O, Rückert T, Lesche R, Toedling J, Kalfon E, Heroult M, Lejeune P, Mönning U, et al: Super-enhancers define a proliferative PGC-1alpha-expressing melanoma subgroup sensitive to BET inhibition. Oncogene. 37:512–521. 2018. View Article : Google Scholar : PubMed/NCBI | |
Tasdemir N, Banito A, Roe JS, Alonso-Curbelo D, Camiolo M, Tschaharganeh DF, Huang CH, Aksoy O, Bolden JE, Chen CC, et al: BRD4 Connects enhancer remodeling to senescence immune surveillance. Cancer Discov. 6:612–629. 2016. View Article : Google Scholar : PubMed/NCBI | |
Togel L, Nightingale R, Chueh AC, Jayachandran A, Tran H, Phesse T, Wu R, Sieber OM, Arango D, Dhillon AS, et al: Dual targeting of bromodomain and extraterminal domain proteins and WNT or MAPK signaling, inhibits c-MYC expression and proliferation of colorectal cancer cells. Mol Cancer Ther. 15:1217–1226. 2016. View Article : Google Scholar : PubMed/NCBI | |
Drier Y, Cotton MJ, Williamson KE, Gillespie SM, Ryan RJ, Kluk MJ, Carey CD, Rodig SJ, Sholl LM, Afrogheh AH, et al: An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma. Nat Genet. 48:265–272. 2016. View Article : Google Scholar : PubMed/NCBI | |
Ceribelli M, Hou ZE, Kelly PN, Huang DW, Wright G, Ganapathi K, Evbuomwan MO, Pittaluga S, Shaffer AL, Marcucci G, et al: A Druggable TCF4- and BRD4-Dependent transcriptional network sustains malignancy in blastic plasmacytoid dendritic cell neoplasm. Cancer Cell. 30:764–778. 2016. View Article : Google Scholar : PubMed/NCBI | |
Liu J, Duan Z, Guo W, Zeng L, Wu Y, Chen Y, Tai F, Wang Y, Lin Y, Zhang Q, et al: Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancer. Nat Commun. 9:52002018. View Article : Google Scholar : PubMed/NCBI | |
Zhang Z, Ma P, Jing Y, Yan Y, Cai MC, Zhang M, Zhang S, Peng H, Ji ZL, Di W, et al: BET Bromodomain Inhibition as a therapeutic strategy in ovarian cancer by downregulating FoxM1. Theranostics. 6:219–230. 2016. View Article : Google Scholar : PubMed/NCBI | |
Mottok A and Gascoyne RD: Bromodomain inhibition in diffuse large B-cell lymphoma-giving MYC a brake. Clin Cancer Res. 21:4–6. 2015. View Article : Google Scholar : PubMed/NCBI | |
Tolani B, Gopalakrishnan R, Punj V, Matta H and Chaudhary PM: Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors. Oncogene. 33:2928–2937. 2014. View Article : Google Scholar : PubMed/NCBI | |
Shen C, Ipsaro JJ, Shi J, Milazzo JP, Wang E, Roe JS, Suzuki Y, Pappin DJ, Joshua-Tor L and Vakoc CR: NSD3-short is an adaptor protein that couples BRD4 to the CHD8 chromatin remodeler. Mol Cell. 60:847–859. 2015. View Article : Google Scholar : PubMed/NCBI | |
Chan KH, Zengerle M, Testa A and Ciulli A: Impact of target warhead and linkage vector on inducing protein degradation: Comparison of bromodomain and extra-terminal (BET) degraders derived from triazolodiazepine (JQ1) and tetrahydroquinoline (I-BET726) BET inhibitor scaffolds. J Med Chem. 61:504–513. 2018. View Article : Google Scholar : PubMed/NCBI | |
Amorim S, Stathis A, Gleeson M, Iyengar S, Magarotto V, Leleu X, Morschhauser F, Karlin L, Broussais F, Rezai K, et al: Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: A dose-escalation, open-label, pharmacokinetic, phase 1 study. Lancet Haematol. 3:e196–e204. 2016. View Article : Google Scholar : PubMed/NCBI | |
Albrecht BK, Gehling VS, Hewitt MC, Vaswani RG, Cote A, Leblanc Y, Nasveschuk CG, Bellon S, Bergeron L, Campbell R, et al: Identification of a Benzoisoxazoloazepine inhibitor (CPI-0610) of the bromodomain and extra-terminal (BET) family as a candidate for human clinical trials. J Med Chem. 59:1330–1339. 2016. View Article : Google Scholar : PubMed/NCBI | |
Siu KT, Ramachandran J, Yee AJ, Eda H, Santo L, Panaroni C, Mertz JA, Sims IR, Cooper MR and Raje N: Preclinical activity of CPI-0610, a novel small-molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma. Leukemia. 31:1760–1769. 2017. View Article : Google Scholar : PubMed/NCBI | |
Zhao L, Okhovat JP, Hong EK, Kim YH and Wood GS: Preclinical studies support combined inhibition of bet family proteins and histone deacetylases as epigenetic therapy for cutaneous t-cell lymphoma. Neoplasia. 21:82–92. 2018. View Article : Google Scholar : PubMed/NCBI | |
Tripathy D, Bardia A and Sellers WR: Ribociclib (LEE011): Mechanism of action and clinical impact of this selective cyclin-dependent kinase 4/6 Inhibitor in various solid tumors. Clin Cancer Res. 23:3251–3262. 2017. View Article : Google Scholar : PubMed/NCBI | |
Geoerger B, Bourdeaut F, DuBois SG, Fischer M, Geller JI, Gottardo NG, Marabelle A, Pearson A, Modak S, Cash T, et al: A phase I study of the CDK4/6 inhibitor ribociclib (LEE011) in pediatric patients with malignant rhabdoid tumors, neuroblastoma and other solid tumors. Clin Cancer Res. 23:2433–2441. 2017. View Article : Google Scholar : PubMed/NCBI | |
Ribociclib extends survival in HR+ breast cancer. Cancer Discov. 8:OF52018. View Article : Google Scholar | |
Ribociclib approved for advanced breast cancer. Cancer Discov. 7:OF32017. View Article : Google Scholar | |
Cheng W, Yang Z, Wang S, Li Y, Wei H, Tian X and Kan Q: Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures. Eur J Med Chem. 164:615–639. 2019. View Article : Google Scholar : PubMed/NCBI | |
Nagaraja S, Vitanza NA, Woo PJ, Taylor KR, Liu F, Zhang L, Li M, Meng W, Ponnuswami A, Sun W, et al: Transcriptional dependencies in diffuse intrinsic pontine glioma. Cancer Cell. 31:635–652, 2017.e6. View Article : Google Scholar : PubMed/NCBI | |
Cayrol F, Praditsuktavorn P, Fernando TM, Kwiatkowski N, Marullo R, Calvo-Vidal MN, Phillip J, Pera B, Yang SN, Takpradit K, et al: THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors. Nat Commun. 8:142902017. View Article : Google Scholar : PubMed/NCBI | |
Ma X, Kuang X, Xia Q, Huang Z, Fan Y, Ning J, Wen J, Zhang H, Yan J, Zhang Q, et al: Covalent CDK7 inhibitor THZ1 inhibits myogenic differentiation. J Cancer. 9:3149–3155. 2018. View Article : Google Scholar : PubMed/NCBI | |
Ali I, Choi G and Lee K: BET inhibitors as anticancer agents: A patent review. Recent Pat Anticancer Drug Discov. 12:340–364. 2017. View Article : Google Scholar : PubMed/NCBI | |
Henssen A, Althoff K, Odersky A, Beckers A, Koche R, Speleman F, Schafers S, Bell E, Nortmeyer M, Westermann F, et al: Targeting MYCN-Driven Transcription By BET-Bromodomain inhibition. Clin Cancer Res. 22:2470–2481. 2016. View Article : Google Scholar : PubMed/NCBI | |
Donati B, Lorenzini E and Ciarrocchi A: BRD4 and cancer: Going beyond transcriptional regulation. Mol Cancer. 17:1642018. View Article : Google Scholar : PubMed/NCBI | |
Berthon C, Raffoux E, Thomas X, Vey N, Gomez-Roca C, Yee K, Taussig DC, Rezai K, Roumier C, Herait P, et al: Bromodomain inhibitor OTX015 in patients with acute leukaemia: A dose-escalation, phase 1 study. Lancet Haematol. 3:e186–e195. 2016. View Article : Google Scholar : PubMed/NCBI | |
Stathis A, Zucca E, Bekradda M, Gomez-Roca C, Delord JP, de La Motte RT, Uro-Coste E, de Braud F, Pelosi G and French CA: Clinical response of carcinomas harboring the BRD4-NUT oncoprotein to the targeted bromodomain inhibitor OTX015/MK-8628. Cancer Discov. 6:492–500. 2016. View Article : Google Scholar : PubMed/NCBI | |
Piquereau J, Boet A, Pechoux C, Antigny F, Lambert M, Gressette M, Ranchoux B, Gambaryan N, Domergue V, Mumby S, et al: The BET Bromodomain Inhibitor I-BET-151 induces structural and functional alterations of the heart mitochondria in healthy male mice and rats. Int J Mol Sci. 20:15272019. View Article : Google Scholar | |
Mustafi S, Camarena V, Qureshi R, Yoon H, Volmar CH, Huff TC, Sant DW, Zheng L, Brothers SP, Wahlestedt C, et al: Vitamin C supplementation expands the therapeutic window of BETi for triple negative breast cancer. Ebiomedicine. 43:201–210. 2019. View Article : Google Scholar : PubMed/NCBI | |
Shen H, Xu W, Guo R, Rong B, Gu L, Wang Z, He C, Zheng L, Hu X, Hu Z, et al: Suppression of enhancer overactivation by a RACK7-histone demethylase complex. Cell. 165:331–342. 2016. View Article : Google Scholar : PubMed/NCBI | |
Katerndahl C, Heltemes-Harris LM, Willette M, Henzler CM, Frietze S, Yang R, Schjerven H, Silverstein K, Ramsey LB, Hubbard G, et al: Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival. Nat Immunol. 18:694–704. 2017. View Article : Google Scholar : PubMed/NCBI | |
Gryder BE, Yohe ME, Chou HC, Zhang X, Marques J, Wachtel M, Schaefer B, Sen N, Song Y, Gualtieri A, et al: PAX3-FOXO1 establishes myogenic super enhancers and confers BET bromodomain vulnerability. Cancer Discov. 7:884–899. 2017. View Article : Google Scholar : PubMed/NCBI | |
Ott CJ, Federation AJ, Schwartz LS, Kasar S, Klitgaard JL, Lenci R, Li Q, Lawlor M, Fernandes SM, Souza A, et al: Enhancer architecture and essential core regulatory circuitry of chronic lymphocytic leukemia. Cancer Cell. 34:982–995.e7e0. 2018. View Article : Google Scholar : PubMed/NCBI | |
Schmidt SF, Larsen BD, Loft A, Nielsen R, Madsen JG and Mandrup S: Acute TNF-induced repression of cell identity genes is mediated by NF κB-directed redistribution of cofactors from super-enhancers. Genome Res. 25:1281–1294. 2015. View Article : Google Scholar : PubMed/NCBI | |
Biswas S and Rao CM: Epigenetics in cancer: Fundamentals and beyond. Pharmacol Ther. 173:118–134. 2017. View Article : Google Scholar : PubMed/NCBI | |
Dzobo K, Senthebane DA, Thomford NE, Rowe A, Dandara C and Parker MI: Not everyone fits the mold: Intratumor and intertumor heterogeneity and innovative cancer drug design and development. Omics. 22:17–34. 2018. View Article : Google Scholar : PubMed/NCBI | |
Kelly AD and Issa JJ: The promise of epigenetic therapy: Reprogramming the cancer epigenome. Curr Opin Genet Dev. 42:68–77. 2017. View Article : Google Scholar : PubMed/NCBI | |
Mill CP, Fiskus W, DiNardo CD, Qian Y, Raina K, Rajapakshe K, Perera D, Coarfa C, Kadia TM, Khoury JD, et al: RUNX1 targeted therapy for AML expressing somatic or germline mutation in RUNX1. Blood. 134:59–73. 2019. View Article : Google Scholar : PubMed/NCBI | |
Mansour MR, Abraham BJ, Anders L, Berezovskaya A, Gutierrez A, Durbin AD, Etchin J, Lawton L, Sallan SE, Silverman LB, et al: Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science. 346:1373–1377. 2014. View Article : Google Scholar : PubMed/NCBI | |
Gröschel S, Sanders MA, Hoogenboezem R, de Wit E, Bouwman B, Erpelinck C, van der Velden V, Havermans M, Avellino R, van Lom K, et al: A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia. Cell. 157:369–381. 2014. View Article : Google Scholar : PubMed/NCBI | |
Marsman J, Gimenez G, Day RC, Horsfield JA and Jones GT: A non-coding genetic variant associated with abdominal aortic aneurysm alters ERG gene regulation. Hum Mol Genet. 29:554–565. 2020. View Article : Google Scholar : PubMed/NCBI | |
Kleinstern G, Yan H, Hildebrandt M, Vijai J, Berndt SI, Ghesquieres H, McKay J, Wang SS, Nieters A, Ye Y, et al: Inherited variants at 3q13.33 and 3p24.1 are associated with risk of diffuse large B-cell lymphoma and implicate immune pathways. Hum Mol Genet. 29:70–79. 2020.PubMed/NCBI | |
He Y, Timofeeva M, Li X, Din F, Blackmur JP, Vaughan-Shaw P, Svinti V, Farrington SM, Campbell H, Dunlop MG, et al: A comprehensive study of the effect on colorectal cancer survival of common germline genetic variation previously linked with cancer prognosis. Cancer Epidemiol Biomarkers Prev. 28:1944–1946. 2019. View Article : Google Scholar : PubMed/NCBI | |
Cong Z, Li Q, Yang Y, Guo X, Cui L and You T: The SNP of rs6854845 suppresses transcription via the DNA looping structure alteration of super-enhancer in colon cells. Biochem Biophys Res Commun. 514:734–741. 2019. View Article : Google Scholar : PubMed/NCBI | |
Zhu DL, Chen XF, Hu WX, Dong SS, Lu BJ, Rong Y, Chen YX, Chen H, Thynn HN, Wang NN, et al: Multiple functional variants at 13q14 risk locus for osteoporosis regulate RANKL expression through long-range super-enhancer. J Bone Miner Res. 33:1335–1346. 2018. View Article : Google Scholar : PubMed/NCBI | |
Eid A, Alshareef S and Mahfouz MM: CRISPR base editors: Genome editing without double-stranded breaks. Biochem J. 475:1955–1964. 2018. View Article : Google Scholar : PubMed/NCBI | |
Leenay RT, Maksimchuk KR, Slotkowski RA, Agrawal RN, Gomaa AA, Briner AE, Barrangou R and Beisel CL: Identifying and visualizing functional PAM diversity across CRISPR-Cas systems. Mol Cell. 62:137–147. 2016. View Article : Google Scholar : PubMed/NCBI | |
Jiang F and Doudna JA: CRISPR-Cas9 structures and mechanisms. Annu Rev Biophys. 46:505–529. 2017. View Article : Google Scholar : PubMed/NCBI | |
Kosicki M, Tomberg K and Bradley A: Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements. Nat Biotechnol. 36:765–771. 2018. View Article : Google Scholar : PubMed/NCBI | |
Anzalone AV, Randolph PB, Davis JR, Sousa AA, Koblan LW, Levy JM, Chen PJ, Wilson C, Newby GA, Raguram A and Liu DR: Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 576:149–157. 2019. View Article : Google Scholar : PubMed/NCBI | |
Fernandes Q: Therapeutic strategies in Sickle Cell Anemia: The past present and future. Life Sci. 178:100–108. 2017. View Article : Google Scholar : PubMed/NCBI | |
Vu M, Li R, Baskfield A, Lu B, Farkhondeh A, Gorshkov K, Motabar O, Beers J, Chen G, Zou J, et al: Neural stem cells for disease modeling and evaluation of therapeutics for Tay-Sachs disease. Orphanet J Rare Dis. 13:1522018. View Article : Google Scholar : PubMed/NCBI | |
Liu X, Zhang Y, Chen Y, Li M, Zhou F, Li K, Cao H, Ni M, Liu Y, Gu Z, et al: In situ capture of chromatin interactions by biotinylated dCas9. Cell. 170:1028–1043.e19e0. 2017. View Article : Google Scholar : PubMed/NCBI |